Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

Gaps in the evidence for treatment decisions in cystic fibrosis: a systematic review.

Rowbotham NJ, Smith S, Prayle AP, Robinson KA, Smyth AR.

Thorax. 2019 Mar;74(3):229-236. doi: 10.1136/thoraxjnl-2017-210858. Epub 2018 Oct 9.

PMID:
30301819
2.

Do guidelines for treating chest disease in children use Cochrane Reviews effectively? A systematic review.

Prayle AP, Cox T, Smith SJ, Rycroft-Malone J, Thomas KS, Hughes DA, Smyth AR.

Thorax. 2017 Apr 26. pii: thoraxjnl-2016-208790. doi: 10.1136/thoraxjnl-2016-208790. [Epub ahead of print]

3.

Growth and nutrition in children with ataxia telangiectasia.

Stewart E, Prayle AP, Tooke A, Pasalodos S, Suri M, Bush A, Bhatt JM.

Arch Dis Child. 2016 Dec;101(12):1137-1141. doi: 10.1136/archdischild-2015-310373. Epub 2016 Aug 29.

4.

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.

Hurley MN; review co-authors, Prayle AP, Flume P.

Paediatr Respir Rev. 2015 Sep;16(4):246-8. doi: 10.1016/j.prrv.2015.07.002. Epub 2015 Jul 29. Review. No abstract available.

PMID:
26298057
5.

The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison.

Prayle AP, Jain K, Touw DJ, Koch BC, Knox AJ, Watson A, Smyth AR.

J Cyst Fibros. 2016 Jul;15(4):510-7. doi: 10.1016/j.jcf.2015.07.012. Epub 2015 Aug 15.

6.

Intravenous antibiotics for pulmonary exacerbations in people with cystic fibrosis.

Hurley MN, Prayle AP, Flume P.

Cochrane Database Syst Rev. 2015 Jul 30;(7):CD009730. doi: 10.1002/14651858.CD009730.pub2. Review.

PMID:
26226131
7.

Rate of improvement of CF life expectancy exceeds that of general population--observational death registration study.

Hurley MN, McKeever TM, Prayle AP, Fogarty AW, Smyth AR.

J Cyst Fibros. 2014 Jul;13(4):410-5. doi: 10.1016/j.jcf.2013.12.002. Epub 2014 Jan 10.

8.

Target renal damage: the microvascular associations of increased aortic stiffness in patients with COPD.

John M, Hussain S, Prayle A, Simms R, Cockcroft JR, Bolton CE.

Respir Res. 2013 Mar 5;14:31. doi: 10.1186/1465-9921-14-31.

9.

From pipeline to patient: new developments in cystic fibrosis therapeutics.

Prayle AP, Smyth AR.

Expert Opin Pharmacother. 2013 Feb;14(3):323-9. doi: 10.1517/14656566.2013.769958. Review.

PMID:
23374028
10.

A healthy nation: strengthening child health research in the UK.

Modi N, Clark H, Wolfe I, Costello A, Budge H; writing group of the Royal College of Paediatrics and Child Health Commission on Child Health Research, Goodier R, Hyde MJ, Lumsden D, Prayle A, Roland D.

Lancet. 2013 Jan 5;381(9860):73-87. doi: 10.1016/S0140-6736(12)61818-2. Epub 2012 Nov 20.

PMID:
23176802
11.

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis.

Hurley MN, Prayle AP; Cochrane Cystic Fibrosis and Genetic Disorders Group.

Paediatr Respir Rev. 2012 Sep;13(3):160-1. doi: 10.1016/j.prrv.2012.04.005. Epub 2012 May 29. No abstract available.

PMID:
22726872
12.

Compliance with mandatory reporting of clinical trial results on ClinicalTrials.gov: cross sectional study.

Prayle AP, Hurley MN, Smyth AR.

BMJ. 2012 Jan 3;344:d7373. doi: 10.1136/bmj.d7373.

PMID:
22214756
13.

Delayed publication of clinical trials in cystic fibrosis.

Hurley MN, Prayle AP, Smyth AR.

J Cyst Fibros. 2012 Jan;11(1):14-7. doi: 10.1016/j.jcf.2011.08.004. Epub 2011 Sep 1.

14.

Karyomegalic-like nephropathy, Ewing's sarcoma and ifosfamide therapy.

McCulloch T, Prayle A, Lunn A, Watson AR.

Pediatr Nephrol. 2011 Jul;26(7):1163-6. doi: 10.1007/s00467-011-1815-z. Epub 2011 Mar 18.

PMID:
21424282
15.

Pneumonia in the developed world.

Prayle A, Atkinson M, Smyth A.

Paediatr Respir Rev. 2011 Mar;12(1):60-9. doi: 10.1016/j.prrv.2010.09.012. Epub 2010 Oct 14. Review.

PMID:
21172677
16.

Percutaneous lines for delivering intravenous antibiotics in people with cystic fibrosis.

Prayle AP, Hurley MN, Smyth AR.

Cochrane Database Syst Rev. 2010 Nov 10;(11):CD008243. doi: 10.1002/14651858.CD008243.pub2. Review.

PMID:
21069703
17.

Aminoglycoside use in cystic fibrosis: therapeutic strategies and toxicity.

Prayle A, Smyth AR.

Curr Opin Pulm Med. 2010 Nov;16(6):604-10. doi: 10.1097/MCP.0b013e32833eebfd. Review.

PMID:
20814306
18.

Side effects of aminoglycosides on the kidney, ear and balance in cystic fibrosis.

Prayle A, Watson A, Fortnum H, Smyth A.

Thorax. 2010 Jul;65(7):654-8. doi: 10.1136/thx.2009.131532. Review.

Supplemental Content

Loading ...
Support Center